Dr. Zahra Rattray participated in the “Developability of new modality therapeutics” session at PharmSci 2025 (11 September 2025, Cardiff, UK), organized by the Joint Pharmaceutical Analysis Group (JPAG) within the Academy of Pharmaceutical Sciences. Her role was as an oral invited presentation. 

In her presentation, she discussed advanced analytical strategies to assess the developability of emerging therapeutic modalities—such as antibody‑drug conjugates and nanomedicines—with a focus on identifying and characterizing critical quality attributes early in development. While the detailed methodological data were not fully publicized, her work draws upon her lab’s expertise using field‑flow fractionation, light‑scattering, mass-based counting, and other bioanalytical tools to probe stability, aggregation, and formulation behavior. 

The key message emphasized how robust, multi-dimensional characterization can de-risk early-stage development, guide formulation design, and accelerate translation into clinical candidates. As a result of her participation, the session generated momentum around integrating cutting-edge analytics into modality development pipelines and fostered discussion among academics and industry about collaborative frameworks for critical quality attribute profiling.​